State of Michigan Retirement System cut its stake in Integra LifeSciences Holdings Co. (NASDAQ:IART – Get Rating) by 1.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,190 shares of the life sciences company’s stock after selling 300 shares during the period. State of Michigan Retirement System’s holdings in Integra LifeSciences were worth $983,000 at the end of the most recent quarter.
Other institutional investors have also added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC boosted its holdings in Integra LifeSciences by 73.7% in the first quarter. Steward Partners Investment Advisory LLC now owns 707 shares of the life sciences company’s stock valued at $45,000 after acquiring an additional 300 shares during the last quarter. First Horizon Advisors Inc. acquired a new position in Integra LifeSciences in the second quarter valued at approximately $54,000. Covestor Ltd lifted its stake in Integra LifeSciences by 63.0% in the first quarter. Covestor Ltd now owns 1,558 shares of the life sciences company’s stock valued at $100,000 after buying an additional 602 shares during the period. Captrust Financial Advisors lifted its stake in Integra LifeSciences by 95.0% in the first quarter. Captrust Financial Advisors now owns 2,003 shares of the life sciences company’s stock valued at $129,000 after buying an additional 976 shares during the period. Finally, Parametrica Management Ltd acquired a new position in Integra LifeSciences in the first quarter valued at approximately $215,000. 87.33% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
Several brokerages have issued reports on IART. Piper Sandler dropped their price target on Integra LifeSciences from $55.00 to $50.00 in a research note on Wednesday, August 24th. Truist Financial dropped their price target on Integra LifeSciences from $60.00 to $46.00 and set a “hold” rating on the stock in a research note on Monday, October 17th. Jefferies Financial Group assumed coverage on Integra LifeSciences in a research note on Tuesday, October 11th. They issued a “hold” rating and a $48.00 price target on the stock. Morgan Stanley upped their target price on Integra LifeSciences from $49.00 to $50.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 27th. Finally, Citigroup lowered their target price on Integra LifeSciences from $57.00 to $50.00 in a research report on Wednesday, October 5th. One analyst has rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $57.38.
Integra LifeSciences Trading Up 2.4 %
Integra LifeSciences Company Profile
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services.
- Get a free copy of the StockNews.com research report on Integra LifeSciences (IART)
- Alphabet Stock Offers a Rare Buying Opportunity
- Solar Battery Maker Enphase Clears Buy Point: Can Rally Hold?
- Walt Disney Stock is Set to Reset Expectations
- S&P 500 Component DexCom Set For Further Price, Earnings Growth
- MarketBeat: Week in Review 11/7 – 11/11
Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.